文献速递眼底病与葡萄膜炎青光眼

抗血管内皮生长因子药物对眼压与青光眼的影响:美国眼科学会报告

The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2018-11-22

该报告由美国眼科学会基于PubMed和Cochrane数据库文献(截至2018年4月)制定,评估玻璃体腔注射抗血管内皮生长因子(VEGF)药物对眼压升高和青光眼的影响。结果显示注射后0至30分钟内所有患者出现眼压立即升高并随时间下降,长期眼压升高的数据不一致,且无数据探讨青光眼发病或进展。

要点

  • 玻璃体腔抗VEGF注射后0至30分钟内所有患者眼压立即升高,并随时间下降。
  • 长期眼压升高数据不一致:7项研究报告4%至15%患者注射后9至24个月出现持续眼压升高,6项研究未发现1至36个月眼压长期变化。
  • 无数据评估抗VEGF注射对青光眼发病或进展的影响,需进一步研究确定高危人群。

核心结论

  • 玻璃体腔注射抗VEGF药物导致眼压立即且短暂升高,也可能出现长期眼压升高。
  • 目前数据不足以确定抗VEGF注射对青光眼进展的影响,需进一步研究确定高危人群。

研究设计与样本

  • 美国眼科学会报告,检索PubMed和Cochrane数据库至2018年4月,获得253条独特引用,41篇符合纳入标准并按证据强度评级:2篇I级、17篇II级、15篇III级,另7篇因设计差和缺乏相关性被排除。

主要发现

  • 报告短期眼压升高(0至60分钟)的研究显示,注射后0至30分钟内所有患者眼压立即升高,并随时间下降。
  • 长期眼压升高数据不一致:7项研究报告4%至15%患者在注射后9至24个月出现持续眼压升高,6项研究未发现注射后1至36个月眼压长期变化。
  • 青光眼药物预处理、前房穿刺、玻璃体反流、延长注射间隔和较长眼轴与注射后眼压升高较低相关。
  • 眼压升高与注射类型、注射次数、既存青光眼及注射前眼球减压的关系数据不一致。
  • 所评估的研究中无关于青光眼发病或进展的数据。

关键数值与推荐

  • 短期眼压升高:注射后0至30分钟内所有患者眼压立即升高,并随时间下降。
  • 长期眼压升高:7项研究报告4%至15%患者在注射后9至24个月出现持续眼压升高;6项研究未发现注射后1至36个月眼压长期变化。

临床怎么用

  • 临床应意识到抗VEGF注射后可能出现眼压立即升高及长期升高,需监测眼压。
  • 青光眼药物预处理、前房穿刺或延长注射间隔可能减轻短暂眼压升高的影响,但其临床意义和风险未知。

局限性

  • 长期眼压升高数据不一致,且无数据评估抗VEGF注射对青光眼发病或进展的影响。
  • 减轻短暂眼压升高干预措施的临床意义和相关风险未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the effect of intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents on immediate and long-term intraocular pressure (IOP) elevation and glaucoma. METHODS: Literature searches of the PubMed and Cochrane databases, last conducted in April 2018, yielded 253 unique citations. Of these, 41 met the inclusion criteria and were rated according to the strength of evidence. Two articles were rated level I, 17 were rated level II, and 15 were rated level III; an additional 7 were excluded because of poor study design and lack of relevance to the topic under evaluation. RESULTS: The studies that reported on short-term IOP elevation (i.e., between 0 and 60 minutes) showed that an immediate increase in IOP is seen in all patients when measured between 0 and 30 minutes of intravitreal injection and that the IOP elevation decreases over time. The data on long-term IOP elevation were mixed; 7 studies reported that between 4% and 15% of patients developed sustained elevation of IOP at 9 to 24 months after injection, whereas 6 studies found no long-term change in IOP from 1 to 36 months after injection. Pretreatment with glaucoma medications, anterior chamber tap, vitreous reflux, longer intervals between injections, and longer axial lengths were associated with lower IOP elevations after injection. Data were mixed on the relationship between IOP increase and the type of intravitreal injection, number of intravitreal injections, preexisting glaucoma, and globe decompression before injection. There were no data on the onset or progression of glaucoma in the studies reviewed in this assessment. CONCLUSIONS: Intravitreal injection of anti-VEGF agents results in an immediate and transient increase in IOP. A long-term increase in IOP also may be seen, and further studies are needed to determine at-risk populations. Although there is some suggestion in the literature, there is currently insufficient data to determine the impact of intravitreal anti-VEGF injections on glaucoma progression. Although pretreatment with glaucoma medications, performing anterior chamber paracentesis, or increasing the interval between injections may reduce the impact of transient IOP elevation, the clinical significance and associated risks of these interventions are unknown.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Hoguet A, Chen PP, Junk AK, et al. The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018. PMID: 30472176. doi:10.1016/j.ophtha.2018.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。